News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Media Contact:

Robert Murphy

Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:

609-249-7262

Email:

robert.murphy@otsuka-us.com

Featured News

Press Release

New Report Reveals U.S. Family Caregivers Perform Equivalent of a Staggering $873.5 Billion Worth of Labor, Would Surpass Revenue of Top Global Companies

Findings released today from a new valuation study conducted by Columbia University Mailman School of Public Health, and sponsored by Otsuka America Pharmaceutical, Inc. reveal that if family caregiving was a business entity it would be the largest revenue-generating company in the world

October 24, 2024

Press Release

Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. today announce positive topline interim data from the ongoing Phase 3 clinical trial of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults.

October 22, 2024

All news

Press Release

Otsuka and Sumitomo Revise License Agreement

Otsuka Pharmaceutical Co., Ltd. announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd. and its U.S. subsidiary, Sumitomo Pharma America, Inc.

March 15, 2024

US News

Otsuka Releases Economic and Health Impact Report 2023/2024

Otsuka’s Economic and Health Impact in the United States report is now available. The report highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., McQuade Center for Strategic Research & Development, and Otsuka Precision Health, Inc., formerly known as Otsuka Digital Health, Inc.

March 07, 2024

Press Release

Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical, Co. Ltd., and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).

February 16, 2024

Discover more mental
health and caregiver
perspectives.

VALUED MINDS NEWS

News & Media

Media Contact:

Featured News

All news

Discover more mental health and caregiver perspectives.

Discover more mental
health and caregiver
perspectives.